.png)
14 Years of Excellence: South Korea’s Biggest Biologics Manufacturing Conference
17 - 18 September 2026
Songdo Convensia, Incheon, South Korea
Co-located Events
Sponsors & Media Partners
Special thanks to our event partners, without whom we would not be able to provide this networking, learning, and collaborating platform.
Silver
Bronze
EXHIBITION & NETWORKING
.jpg)
Associate
2026 SPEAKERS
BMK 2026
Jonggu Kim
Director, Quality
Lotte Biologics
South Korea
Woo Chi
Principal Scientist, AAV Technology
Samsung Biologics
South Korea
Dae-Won Kim, Ph.D.
Chief Executive Officer & Founder
ICM Co., Ltd.
South Korea
Paul Song
Chief Executive Officer
NKGen Biotech
United States
Heechung Kwon
Chief Executive Officer
GencellMed
South Korea
Sammi Hsu
Senior Manager
Ever Supreme Biotechnology
Taiwan
Hideto Yamaguchi
Senior Vice President, Head of Regenerative Medicine Technology, Astellas
CEO, Cellafa Biosciences
Japan
Cheng Yi (Jerry) Kuo
Assistant General Manager
UWell Biopharma
Taiwan
Chen Honghang
Global Solution Architect, Life Science Segment
Schneider Electric
Singapore
Prof. Lee Beom Jin
Professor
Ajou University
South Korea
Eric Bishop
VP of Research and Development
Cygnus Technologies
United States
Hemasunder Reddy
Business Development Director
Pfanstiehl, Inc.
United States
Young Jun Seo
CEO
Elonova
South Korea
Agenda At A Glance
CONFERENCE DAY 1 | 17 September 2026 |
|
|
|
|
|
Leadership Panel Discussion
Scaling Biologics & CGT in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies
|
|
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Upstream Processing
Optimizing Cell Culture, Purification and Recovery
|
Discovery
Innovative Pathways in ADC Discovery: Unlocking Next-Gen Targeting Strategies
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Automation & Bioprocessing 4.0
Building Intelligent, Connected Facilities
|
Advancing Pre-Clinical Research
Bringing the Gap: From Pre-Clinical Insights to Clinical Success in ADC Development
|
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Quality & Analytics
Ensuring Precision and Compliance
|
ADC Biopharma Showcase
Pioneering Innovation and Excellence in Antibody-Drug Conjugates
|
| End of Conference Day 1 | |
CONFERENCE DAY 2 | 18 September 2026 |
|
|
|
|
|
Tech Transfer, Scale-Up & CMC Excellence
Bridging Development and Commercialisation
|
Leadership Panel Discussion
Redefining ADC Therapeutics: Addressing Toxicity, Enhancing Efficacy, and the Rise of Dual Payload Designs
|
| Morning Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
CAR-T & CAR-NK Therapies Case Studies
Next-Gen Cell Therapy & Preclinical Innovation
|
Scaling Up ADC Production
Overcoming Challenges in Bioconjugation and Purification
|
| Lunch, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Advancing Gene Therapy
Optimizing Vectors, Editing Technologies, and Smart Manufacturing
|
Optimizing ADC Target Selection and Engineering for Maximum Efficacy
Expanding the Next Wave of Precision Medicines
|
| Afternoon Tea, Exhibition Viewing, Poster Presentations & 1-1 Attendee Networking | |
|
Case Studies in Advanced Modalities
Peptides, Oligonucleotides, and Beyond
|
Advancing Payloads and Linker Technologies for Next-Generation ADCs
|
| End of Conference | |
CONFERENCE AGENDA
Day 1
Thursday, 17 September 2026
8:50
IMAPAC Opening Remarks
8:55
Chairman Opening Remarks
.png)
Leadership Panel Discussion: Scaling Biologics & CGT in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies
9:00
Leadership Panel Discussion: Scaling Biologics & CGT in East Asia: Innovation, Manufacturing Challenges & Collaborative Strategies
- Regional capacity expansion strategies and investment priorities
- Overcoming talent shortages, tech transfer challenges, and cost pressures
- Role of CDMOs, partnerships, and government collaboration
- Outlook for biologics and CGT manufacturing at scale
9:50
Arginine-Glutamate as Ideal Excipient for High Concentration Monoclonal Antibody Formulation.
- Need for higher dose of monoclonal antibodies(mAb) formulations
- Arginine-Glutamate a promising candidate to address concerns of aggregation, viscosity, liquid-liquid phase separation and longer storage
- Mechanism driving mAb stability in formulation containing Arginine-Glutamate
Hemasunder Reddy
Business Development Director, Pfanstiehl, Inc.
10:15
From Ambition to Execution: Why Scaling Biologics in East Asia Is Harder Than Anyone Admits
- Why most biologics scale-up failures are not technology problems, but execution, sequencing, and decision-timing failures
- The uncomfortable trade-offs manufacturing leaders must make between speed, cost, quality, and talent and why avoiding these decisions kills programs
- Where East Asian manufacturers systematically underestimate complexity: process transfer, organizational readiness, and inspection reality
- Hard lessons from scaling biologics and CGT programs that looked perfect on paper but struggled at GMP and commercial scale
10:40
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Upstream Processing: Optimizing Cell Culture, Purification and Recovery
11:15
Advanced Cell Culture Control Strategies for High-Density & High-Titer Processes
- Managing oxygen, pH, and nutrient gradients at scale
- Process robustness vs maximum productivity trade-offs
- Online and offline monitoring strategies
- Lessons from scale-dependent failures
11:40
Building the Digital Foundation for Scalable Biopharma Manufacturing: Unified Operations for Resilience, Compliance, and Efficiency
- Biologics and pharmaceutical manufacturers face increasing pressure to improve operational efficiency, compliance, resilience, and scalability. However, many facilities still rely on fragmented building, utility, and power systems that create silos and limit visibility.
- This talk explores how unified, AI-powered operations can provide a smarter digital foundation for biopharma manufacturing.
- Using Schneider Electric’s EcoStruxure Foresight as an example, the session will show how connected facility operations can improve uptime, streamline lifecycle management, support controlled environments, and enable more future-ready, data-driven operations.
Chen Hong Hang
Global Solution Architect, Life Science Segment, Schneider Electric
12:05
Continuous vs Hybrid Downstream: The Truth Behind What Actually Works in GMP and What Fails at Scale
- Operational and regulatory realities of implementing continuous steps in GMP environments
- Facility footprint, cost, and change-management implications
- Lessons from real implementations where teams succeeded and where they had to revert
- How to future-proof downstream without locking yourself into inflexible designs
12:30
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
Automation & Bioprocessing 4.0: Building Intelligent, Connected Facilities
1:45
From Digital Islands to Connected Manufacturing: Making Bioprocessing 4.0 Actually Work
(TBC)
Hyemi Kim
IT, Head, Lotte Biologics, South Korea
2:10
Advanced Orthogonal Analysis of HCP using Mass Spectrometry
- Overview of Mass Spectrometry in HCP Analytics
- Advantages of MS in Coverage Analysis
- Identification of HCP in DS
- Relative and Absolute Quantification of individual HCPs using MS
Eric Bishop
VP of Research and Development, Cygnus Technologies
2:35
Smart Biomanufacturing: Enabling the Next Generation of Automated Facilities
(TBC)
Reserved for Prof. Kevin Hong
Professor, Gachon University, South Korea
3:00
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Quality & Analytics: Ensuring Precision and Compliance
3:40
Data Integrity 2.0 (Strategic Quality Management and Integrated Lifecycle Collaboration, MAH - CDMO - Suppliers)
- The 2026 Regulatory Paradigm Shift
- Building an Honest Orgnizational Foundation from Quality Culture and Metrics perspective
- Lifecycle Collaboration Model between MAH - CDMO – Supplier
- Roadmap to 2026 and beyond
Jonggu Kim
Director, Quality, Lotte Biologics, South Korea
4:05
Inspection-Ready Manufacturing: Quality, Analytics & Compliance in a Post-Paper World
- What inspectors now expect to see and question
- Managing data integrity across complex processes
- Inspection lessons from recent FDA / EMA / MFDS audits
- Preparing organizations for predictive quality models
4:30
CLOSING KEYNOTE: If I Were Building a New Biologics Facility Today: Lessons from the Frontline
- What worked, what failed, and what to avoid
- Technology decisions with long-term impact
- Managing regulatory and workforce challenges
- Final takeaways for manufacturing leaders
4:55
Chairman Closing Remarks
5:05
End of Conference Day 1
CONFERENCE AGENDA
Day 2
Friday, 18 September 2026
8:50
IMAPAC's Opening Address
8:55
Chairman's Opening Address
Tech Transfer, Scale-Up & CMC Excellence: Bridging Development and Commercialisation
9:00
Fatty acid-conjugated peptide drugs for improved physicochemical and biological performance
Prof. Lee Beom Ju
Professor, Ajou University, South Korea
9:25
Reserved for Solution Provider
9:50
Clinical Development in NK Cell Therapy
(TBC)
Reserved for Cheng Yi (Jerry) Kuo
Assistant General Manager, UWell Biopharma, Taiwan
10:15
Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Exhibition Hall, Ballroom B
CAR-T & CAR-NK Therapies Case Studies: Next-Gen Cell Therapy & Preclinical Innovation
11:00
Use of Troculeucel (Cryopreserved Enhanced Autologous NK Cell Therapy) for Neurodegenerative Diseases
- Troculeucel’s mechanism of action in reducing CSF neuroinflammatory and protein biomarkers.
- Reviewing the early clinical efficacy of Troculeucel in AD, PD, and FTD patients.
- Discuss regulatory landscape in Asia to expedite development and commercialization of Troculeucel
Paul Y. Song
Chief Executive Officer, NKGen Biotech, USA
11:25
Driving Innovation in Cell Therapy Manufacturing with AI and Robotics: From Process Optimization to Regulatory-Ready Platforms
- Feasibility study results on AI-driven process optimization for iPSC-derived NK cell production, utilizing machine learning to analyze process data generated by the dual-arm LabDroid “Maholo” automation system.
- The discussion will cover how AI-enabled data analysis and robotic automation can improve yield, enhance batch-to-batch consistency, and support robust cell quality in advanced cell therapy manufacturing.
- Outline a regulatory strategy for implementing robotic automation in GMP environments, including key considerations from interactions with regulatory agencies.
Dr. Hideto Yamaguchi
Senior Vice President, Head of Regenerative Medicine Technology, Astellas, CEO, Cellafa Biosciences, Japan
11:50
Advancing Allogeneic CAR-T for Solid Tumors: From Phase II Clinical Development to Next-Generation In Vivo CAR-T
- Clinical progress and Phase IIa development strategy of CAR001, an allogeneic off-the-shelf CAR-T therapy for solid tumors.
- Emerging clinical insights from recurrent glioblastoma and other solid tumor indications.
- Manufacturing and scalability considerations for next-generation allogeneic cell therapies.
- Leveraging clinical experience to develop EXO001, an in vivo CAR-T platform.
Sammi Hsu
Senior Manager, Ever Supreme Biotechnology, Taiwan
12:15
Lunch Break, Exhibition Viewing & 1-1 Attendee Networking
Advancing Gene Therapy: Optimizing Vectors, Editing Technologies, and Smart Manufacturing
1:45
ICM-203 AAV Gene Therapy as a Promising DMOAD Candidate for OA Treatment
- Target (Nkx3.2) discovery and validation for OA treatment
- Preclinical validation of ICM-203 for DMOAD activity
- First-in-human clinical development of ICM-203
Dae Won Kim, Ph.D.
CEO & Founder, ICM Co., Ltd., South Korea
2:10
AAV Platform Development in the Challenging Environment
Woo Chi
Principal Scientist, AAV Process Development, Samsung Biologics, South Korea
2:35
In Vivo vs Ex Vivo Gene Editing: Translational Case Studies and Challenges
(TBC)
Heechung Kwon
CEO, GencellMed, South Korea
3:00
Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking
Premier Ballroom A
Case Studies in Advanced Modalities: Peptides, Oligonucleotides, and Beyond
3:45
Riding the GLP-1 Wave: Manufacturing Peptide Therapeutics at Unprecedented Scale
(TBC)
- Capacity constraints and scale-up strategies amid surging GLP-1 demand
- Advances in solid-phase peptide synthesis (SPPS) and purification for commercial production
- Quality control challenges and regulatory considerations for peptide APIs
Reserved for Ivan Horak
CEO, Tikva Allocell, Singapore
4:10
siRNA Therapeutics: From Promising Science to Commercial Manufacturing Reality
- Overview of siRNA mechanisms and the current clinical pipeline
- Key manufacturing challenges: synthesis, conjugation, and lipid nanoparticle formulation
- Lessons from approved siRNA drugs and what they mean for the next wave
4:35
Closing Keynote: The Next Decade of Biologics Manufacturing: What Must Change Now
- Strategic shifts required to remain competitive through 2035
- Talent, technology, and operating model transformation
- Collaboration across industry and regulators
- Final leadership insights and takeaways
5:00
Chairman Closing Remarks
5:05
End of Conference Day 1
By Profile
By Job Title
By Geography
5%
USA
3%
Europe
3%
Taiwan & India
3%
South East Asia
5%
Japan
5%
Singapore
68%
South Korea
3%
Other
5%
USA
3%
Europe
3%
Taiwan & India
3%
South East Asia
5%
Japan
5%
Singapore
68%
South Korea
3%
Other
Our Past Partners
.png)
